Chronic Kidney Disease Clinical Trial
Official title:
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
NCT number | NCT02414841 |
Other study ID # | PRT-201-320 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | August 2015 |
Est. completion date | May 1, 2019 |
Verified date | July 2019 |
Source | Proteon Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This research study is designed to assess the safety and effectiveness of an experimental drug called vonapanitase (PRT-201) in patients both receiving or expecting to receive hemodialysis who have chronic kidney disease and who are undergoing surgery to create a new access point to their bloodstream for hemodialysis. Vonapanitase is a protein that has been shown in previous research studies to help keep vessels patent when applied to the outside surface of the blood vessels (arteries and veins) in patients who undergo surgery to create an arteriovenous fistula (AVF). The purpose of this study is to determine whether vonapanitase when applied to a limited segment of your blood vessel (about 2 inches) immediately after surgery is safe and improves the patency of your AVF.
Status | Completed |
Enrollment | 696 |
Est. completion date | May 1, 2019 |
Est. primary completion date | February 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility |
Inclusion Criteria: 1. Age of at least 18 years. 2. Life expectancy of at least 6 months. 3. Diagnosis of CKD. 4. Planned creation of a new radiocephalic AVF (revision of an existing AVF is not eligible). 5. Ability to understand and comply with the requirements of the entire study and to communicate with the study team. 6. Written informed consent using a document that has been approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC). 7. If female and of childbearing potential (premenopausal and not surgically sterile) must have a negative serum pregnancy test at the screening visit and be willing to use contraception from the time of the screening visit to 2 weeks following study drug administration. Acceptable methods of birth control include abstinence, barrier methods, hormones, or intra-uterine device. Exclusion Criteria: 1. Malignancy or treatment for malignancy within the previous 12 months with the exception of the following cancers if they have been resected: localized basal cell or squamous cell skin cancer, or any cancer in situ. 2. Presence of any significant medical condition that might significantly confound the collection of safety and efficacy data in this study. 3. Previous treatment with vonapanitase (PRT-201). 4. Treatment with any investigational drug within the previous 30 days or investigational antibody therapy within the previous 90 days prior to signing informed consent. |
Country | Name | City | State |
---|---|---|---|
Canada | University of Alberta | Edmonton | Alberta |
Canada | London Health Science Center | London | Ontario |
Canada | McGill University Health Centre- Royal Victoria Hospital | Montreal | Quebec |
Canada | University Health Network Toronto General Hospital | Toronto | Ontario |
Canada | Vancouver General Hospital | Vancouver | British Columbia |
United States | Lehigh Valley Health Network | Allentown | Pennsylvania |
United States | VA Ann Arbor Healthcare System | Ann Arbor | Michigan |
United States | Cardiothoracis and Vascular Surgeons | Austin | Texas |
United States | Lake Washington Vascular Center | Bellevue | Washington |
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | Brigham and Women's Hospital | Boston | Massachusetts |
United States | University of North Carolina at Chapel Hill | Chapel Hill | North Carolina |
United States | University of Chicago | Chicago | Illinois |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | Henry Ford Hospital | Detroit | Michigan |
United States | Lutheran Hospital Network of Indiana | Fort Wayne | Indiana |
United States | Greenwood Leflore Hospital | Greenwood | Mississippi |
United States | Baylor College of Medicine | Houston | Texas |
United States | The Methodist Hospital | Houston | Texas |
United States | The University of Iowa Hospitals and Clinics | Iowa City | Iowa |
United States | Saint Luke's Hospital | Kansas City | Missouri |
United States | Knoxville Kidney Center | Knoxville | Tennessee |
United States | VA Loma Linda Healthcare System | Loma Linda | California |
United States | VA Medical Center Long Beach | Long Beach | California |
United States | Keck University Hospital at USC | Los Angeles | California |
United States | University of Louisville | Louisville | Kentucky |
United States | University of Wisconsin School of Medicine and PH | Madison | Wisconsin |
United States | Tulane University | New Orleans | Louisiana |
United States | New York Presbyterian Hospital-Weill Cornell Medical Center | New York | New York |
United States | SC Nephrology and Hypertension Center, Inc. | Orangeburg | South Carolina |
United States | RenalCare Associates, S.C. | Peoria | Illinois |
United States | AKDHC Medical Research Services, LLC | Phoenix | Arizona |
United States | VA Pittsburg Healthcare System | Pittsburgh | Pennsylvania |
United States | Maine Medical Center | Portland | Maine |
United States | California Institute of Renal Research | San Diego | California |
United States | Kaiser Permanente | San Diego | California |
United States | Kaiser Permanente Northern California | San Francisco | California |
United States | AKDHC Medical Research Services, LLc | Tucson | Arizona |
United States | Banner University Medical Center Tucson | Tucson | Arizona |
United States | Wake Forest | Winston-Salem | North Carolina |
United States | University of Massachusetts Medical Center | Worcester | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Proteon Therapeutics |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Kaplan-Meier Estimate of Secondary AVF Patency | Kaplan-Meier estimate of median time from AVF creation until AVF abandonment (secondary patency) | Median time from AVF creation to AVF abandonment (secondary patency), assessed up to 1 year. | |
Primary | Number of Participants With AVF Use for Hemodialysis | AVF use for hemodialysis is defined as the ability of the study AVF to be successfully cannulated and used for hemodialysis for a minimum of 90 days or at least 30 days prior to a patient's last visit, if hemodialysis has not been initiated at least 90 days prior to the patient's last visit. If AVF use is not defined as above, non-use of the AVF for hemodialysis is defined as an abandoned fistula prior to use; or if hemodialysis is recorded on 2 consecutive visits and there is no cannulation date or duration of use is less than 90 days. The patients who are not categorized as having use or non-use of the AVF have insufficient data to determine AVF use for hemodialysis and will be categorized as having indeterminate use. | Assessed at up to 12 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |